partnerships for both development and marketing: Pfizer/Takeda for Fusilev, Bayer for Zevalin, Topotarget for Belinostat and Allergan for Apaziquone. Moreover, OncoRx is a subsidiary of SPPI located in India that functions as a dependable resource for SPPI
By Don Dion : On Saturday, March 8, the 25-day quiet period on underwriter research that started with Flexion Therapeutics Inc ( FLXN )'s February 11 IPO will expire, allowing the firm's IPO underwriters to publish positive research reports on the injectable pain relief pharmaceutical firm. The ...
topical Botulinum Toxin Type A Gel for the treatment of lateral canthal lines (crow's feet). It will complete with Allergan 's ( AGN ) blockbuster injectable treatment Botox . Botulinum is in Phase 3 trials in the U.S. Anaylsts' price targets
sellers decreased their holdings by more than 10%. Allergan ( AGN ) operates as a multi-specialty healthcare company ..... Insider selling during the last 30 days Here is a table of Allergan 's insider activity during the last 30 days. Name
40.83 1.07 Medium 27,891 1 Allergan AGN 3 Wide 124.57 1.08 Medium 36,899 1 AmscBrgnABC 4 Wide ..... 40.83 1.07 Medium 27,891 1 Allergan AGN 3 Wide 124.57 1.08 Medium 36 ..... conviction new-money purchase of Allergan ( AGN ), it was limited to the following
By OptionMonster : Last week, stocks continued their rebound from the edge of the abyss. Investors responded positively to a dovish combination of comments from Speaker of the House John Boehner and new Federal Reserve Chairwoman Janet Yellen. Mr. Boehner said he would not pursue another ...
By Brian Marckx : Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks. Snapshot VeriTeQ Corporation ( OTCQB:VTEQ ) went public in July 2013. The company is engaged in
Allergan ( AGN ) Q4 2013 Earnings Call February 05, 2014 11:00 am ET Executives James M. Hindman - Chief Financial Officer David E. I. Pyott
Allergan ’s fourth-quarter results and 2014 outlook ..... 2014. Recent favorable developments for Allergan , including newly issued patents for Restasis ..... potential and support our wide moat rating on Allergan . Our 2014 non-GAAP EPS estimate of
Allergan ( AGN -1.2% ) net profit $312.9M vs $324.2M Total specialty pharmaceuticals net sales +14%, total core medical devices